QIAGEN NV provides sample and assay technologies. Its sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules, such as the DNA of a specific virus, visible for subsequent analysis. The company provides these products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. The company's technologies focus on the following healthcare needs: Prevention, Profiling, Personalized Healthcare, and Point of Need. Prevention includes screening of non-symptomatic patients to detect risks to specific diseases. Profiling provides testing of symptomatic patients to determine the type and severity of an infection. Personalized Healthcare includes the testing of pre-diagnosed patients to guide treatment decisions and medicine use. Point of need applies molecular testing in settings with no laboratory in emerging markets. QIAGEN was founded by Detlev H. Riesner, Metin Colpan, and Karsten Henco in 1984, and is headquartered in Venlo, Netherlands.
Similar to: Pressure BioSciences, Inc.
Venlo, LI 5911 KJ
SIC Code: 3826